Pavord Ian D, Jones Paul W, Burgel Pierre-Régis, Rabe Klaus F
Respiratory Medicine Unit, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Division of Clinical Science, St George's, University of London, London, UK.
Int J Chron Obstruct Pulmon Dis. 2016 Feb 19;11 Spec Iss(Spec Iss):21-30. doi: 10.2147/COPD.S85978. eCollection 2016.
Exacerbations of chronic obstructive pulmonary disease (COPD) are defined as sustained worsening of a patient's condition beyond normal day-to-day variations that is acute in onset, and that may also require a change in medication and/or hospitalization. Exacerbations have a significant and prolonged impact on health status and outcomes, and negative effects on pulmonary function. A significant proportion of exacerbations are unreported and therefore left untreated, leading to a poorer prognosis than those treated. COPD exacerbations are heterogeneous, and various phenotypes have been proposed which differ in biologic basis, prognosis, and response to therapy. Identification of biomarkers could enable phenotype-driven approaches for the management and prevention of exacerbations. For example, several biomarkers of inflammation can help to identify exacerbations most likely to respond to oral corticosteroids and antibiotics, and patients with a frequent exacerbator phenotype, for whom preventative treatment is appropriate. Reducing the frequency of exacerbations would have a beneficial impact on patient outcomes and prognosis. Preventative strategies include modification of risk factors, treatment of comorbid conditions, the use of bronchodilator therapy with long-acting β2-agonists or long-acting muscarinic antagonists, and inhaled corticosteroids. A better understanding of the mechanisms underlying COPD exacerbations will help to optimize use of the currently available and new interventions for preventing and treating exacerbations.
慢性阻塞性肺疾病(COPD)急性加重被定义为患者病情持续恶化,超出正常日常变化范围,起病急,可能还需要改变药物治疗和/或住院治疗。急性加重对健康状况和预后有重大且持久的影响,并对肺功能产生负面影响。相当一部分急性加重未被报告,因此未得到治疗,导致预后比接受治疗的患者更差。COPD急性加重具有异质性,已经提出了各种表型,它们在生物学基础、预后和对治疗的反应方面存在差异。生物标志物的识别可以实现基于表型的急性加重管理和预防方法。例如,几种炎症生物标志物可以帮助识别最有可能对口服糖皮质激素和抗生素有反应的急性加重,以及适合进行预防性治疗的频繁急性加重表型患者。降低急性加重的频率将对患者的结局和预后产生有益影响。预防策略包括改变危险因素、治疗合并症、使用长效β2受体激动剂或长效毒蕈碱拮抗剂进行支气管扩张剂治疗以及吸入糖皮质激素。更好地理解COPD急性加重的潜在机制将有助于优化目前可用的和新的预防和治疗急性加重干预措施的使用。